TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26165528
Drug: Non-rebreather mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-rebreather mask (NRB) at 10 L·min⁻¹
Study: 18182467
Drug: PE +
Normalized name: Chlorpheniramine Maleate/Phenylephrine Hydrochloride 4 MG-10 MG Oral Tablet [SINUS PE + ALLERGY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE + F (oral fludrocortisone, 0.2 mg)
Study: 2692971
Drug: Naftifine (1%)
DrugBank: Naftifine (DB00735)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naftifine (1%) spray
Study: 15930418
Drug: Zoster vaccine
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoster vaccine
Study: 9266790
Drug: Intravenous dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dipyridamole infusion (0.56 mg/kg over a 4‐minute period) 48 to 96 hours after onset of symptoms
Study: 6384073
Drug: Indoprofen 400
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 400 mg
Study: 10194770
Drug: HIV myelitis
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV myelitis in drug users (17%)
Study: 6990675
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg the night before and 400 mg on the morning of surgery
Study: 19092349
Drug: Methylprednisolone treatment
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone treatment
Study: 28235531
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose (0.5mg/kg) of propofol with divided remifentanil injections and moderate hyperventilation (ETCO2 of 30‐35mmHg) (group RP/H)
Study: 24524031
Drug: Haloperidol 2
Normalized name: haloperidol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2 mg
Study: 2611360
Drug: Flurbiprofen without
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen without Maalox (antacid)
Study: 25344393
Drug: TEAMS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEAMS therapy
Study: 8253920
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone
Study: 9373732
Drug: IFN alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN alpha-2b (3 x 10(6) IU, 3 times weekly)
Study: 24925985
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (paroxetine)
Study: 18977955
Drug: RIX4414 administered
Normalized name: HUMAN ROTAVIRUS A TYPE G1P(8) STRAIN RIX4414 LIVE ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 administered separately at 3 and 5 months
Study: 15358571
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-treated area for topical CS application).
Study: 3054280
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of acarbose treatment
Study: 8679790
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg TRH intravenously 20 min before ECT
Study: 27486878
Drug: PF induction
Normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF induction chemotherapy (cisplatin and fluorouracil)
Study: 19097665
Drug: Sitagliptin 100mg
Normalized name: Sitagliptin 100mg Oral tablet
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100mg once daily
Study: 22030199
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1 mL of lidocaine gel 2% (control)
Study: 15029476
Drug: Good common
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good common practice drugs
Study: 9223201
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL 0.5% bupivacaine with 1:200,000 epinephrine and 1 mg preservative-free morphine (group BUP-MORPH)
Study: 9223201
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL normal saline with 1:200,000 epinephrine and 1 mg preservative-free morphine (group MORPH)
Study: 31945074
Drug: Weekly training
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly training interval
Study: 19509107
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human TSH injections (0.9 mg im per 2 consecutive days) - group B
Study: 10919900
Drug: Artificial tears
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears four times daily
Study: 2697690
Drug: Glycine fortified
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine fortified oral rehydration solution (ORS)
Study: 21529904
Drug: Maintenance low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maintenance low-dose paclitaxel 40 mg/m²/week for 24 weeks
Study: 21529904
Drug: Maintenance low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maintenance low-dose paclitaxel
Study: 9047153
Drug: Control patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients receiving OKT3 therapy
Study: 27127998
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 800 mcg
Study: 27127998
Drug: Vilanterol (VI)
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilanterol (VI) 100 mcg
Study: 16940830
Drug: Twice-daily amoxicillin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily amoxicillin
Study: 11015795
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline injection (placebo; n = 589 in 1997-1998; n = 604 in 1998-1999)
Study: 7478692
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic cream
Study: 27633651
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream
Study: 6991103
Drug: Pseudomonas vaccine
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas vaccine
Study: 17679725
Drug: Centrally assessed
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrally assessed hormone receptor status
Study: 1980464
Drug: Flurazepam 30
Normalized name: flurazepam 30 mg oral capsule
DrugBank: Flurazepam (DB00690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurazepam 30 mg
Study: 23756569
Drug: Non-fermented dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fermented dairy diet (butter, cream, ice cream)
Study: 21774289
Drug: Intracameral triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral triamcinolone acetonide and gentamicin injections followed by topical tobramycin eye drops four times daily for one week (IC TA group, n=30)
Study: 3136064
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg disopyramide
Study: 3136064
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg flecainide
Study: 29153295
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of 37.5 mg ropivacaine plus 40 mg methylprednisolone (active group, n=49)
Study: 11994249
Drug: JTT-705 900
Normalized name: JTT-251
DrugBank: JTT-251 (DB18174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTT-705 900 mg
Study: 7613531
Drug: Antiandrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiandrogen therapy
Study: 15459137
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (500 microg b.i.d. by inhalation and 100 microg intranasally once daily)
Study: 21962063
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 50 mg three times daily
Study: 3210111
Drug: Erythromycin treatment
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin treatment
Study: 30547316
Drug: F14512 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F14512 at dose level 5 mg/m2/day
Study: 25851025
Drug: Traditional Iranian
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Iranian Pharmacy formulation
Study: 29718143
Drug: Covering empirical
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Covering empirical antibiotic treatment (EAT)
Study: 15161956
Drug: Tacrolimus for
Normalized name: tacrolimus Granules for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus for cyclosporin (C(0): 5-10 ng/ml)
Study: 15161956
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of standard therapy (C(0): 163 ng/ml (145-215 ng/ml))
Study: 2951158
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg thrice daily
Study: 8223138
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg levodropropizine
Study: 28192113
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg dihydrocodeine
Study: 8113478
Drug: Problem-Solving Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Therapy (PST)
Study: 24326106
Drug: Verteporfin photodynamic
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin photodynamic therapy (vPDT) (group III, n = 55)
Study: 15841781
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine hydrochloride gel (Group 2)
Study: 15157139
Drug: Treatment impact
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment impact
Study: 21199833
Drug: Satavaptan 25
Normalized name: Satavaptan
DrugBank: Satavaptan (DB14923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satavaptan 25 mg/day in CHF patients
Study: 18001442
Drug: Oral clindamycin
Normalized name: clindamycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clindamycin
Study: 23946318
Drug: eletriptan 40
Normalized name: eletriptan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eletriptan 40 mg (ELE-40)
Study: 2419384
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy with cat- and dog-dander extracts
Study: 29210957
Drug: Caffeine gum
Normalized name: caffeine Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine gum (CAF) 400 mg; 4.1 ± 0.5 mg·kg
Study: 7051805
Drug: L‐PAM
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L‐PAM
Study: 8855175
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (IFN-alpha) 5 MU three times weekly for 6 months
Study: 12562140
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P receptor antagonists (SPAs) aprepitant (MK‐0869) and compound A
Study: 31833059
Drug: 12-hour maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12-hour maintenance dose of magnesium sulfate (MgSO4)
Study: 8403157
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg.kg‐1) premedication, all groups
Study: 22234000
Drug: parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: parecoxib 40 mg IV
Study: 22234000
Drug: ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoprofen 100 mg IV
Study: 26427279
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of torasemide
Study: 26427279
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of spironolactone
Study: 31842852
Drug: Local ingredients-based
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local ingredients-based supplement (LIBS) - 100 g of LIBS plus 25.2 g of sugar with 8 ml oil
Study: 23657969
Drug: Tibetan Sound
Normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tibetan Sound Meditation (TSM) - two weekly sessions for 6 weeks
Study: 30080227
Drug: Social-based activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social-based activities (n=47), 60 minutes/session, twice per week for 24 weeks
Study: 1936753
Drug: Acute administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute administration of verapamil 160 mg
Study: 1936753
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment of verapamil 240 mg/day for six months
Study: 8919573
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage ECT
Study: 8919573
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage ECT
Study: 16518530
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg atorvastatin
Study: 22206075
Drug: RT001 Botulinum
Normalized name: CLOSTRIDIUM BOTULINUM
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT001 Botulinum Toxin Type A Topical Gel
Study: 11450599
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with cat epithelial extract
Study: 22484874
Drug: Composite resin
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite resin (34% Tooth Conditioner Gel + Adper Single Bond 2 + Z100)
Study: 15297790
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) treatment (16-32 mg/kg/day) for 6 days
Study: 1586708
Drug: Higher-dose methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose methylprednisolone (HDM)
Study: 3289598
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg twice daily alone
Study: 21273177
Drug: Concurrent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent docetaxel (75 mg/m² I.V.) followed by bortezomib (1.6 mg/m² I.V. on days 1 and 8)
Study: 21273177
Drug: Sequential docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential docetaxel (75 mg/m² I.V.) followed by bortezomib (1.6 mg/m² I.V. on days 2 and 8)
Study: 19446148
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg weekly oral alendronate
Study: 23047956
Drug: Patient ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient ratings of treatment
Study: 9672330
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for 8 weeks
Study: 18303097
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose (120 mcg ipratropium bromide and 600 mcg of salbutamol using metered dose inhaler (MDI) and spacer)
Study: 8386779
Drug: Intracorporeal injections
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracorporeal injections with sodium bicarbonate (0.03 mEq.)
Study: 21537127
Drug: DEB loaded
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DEB loaded with 50 mg doxorubicin
Study: 17416113
Drug: Gliclazide 80
Normalized name: gliclazide 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 80 mg tablet from EMS Indústria Farmacêutica Ltda.
Study: 16948483
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (VC) 3 g/d
Study: 9366314
Drug: Potassium-magnesium citrate
Normalized name: potassium magnesium aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-magnesium citrate (42 mEq. potassium, 21 mEq. magnesium, and 63 mEq. citrate) daily for up to 3 years
Study: 12160194
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg twice daily
Study: 31926085
Drug: Amoxicillin prescription
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin prescription in adults
Study: 19453319
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitors
Study: 2906696
Drug: Intrarenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarenal infusion of an alpha 1‐antagonist
Study: 2906696
Drug: Blockade of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blockade of alpha 2‐receptors
Study: 12448241
Drug: Cefazolin single-dose
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin single-dose regimen
Study: 10438352
Drug: Zidovudine and
Normalized name: zidovudine and lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine and lamivudine (two-drug therapy)
Study: 21822907
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no OTRa administration).
Study: 1687407
Drug: Intravenous beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous beta-blockers
Study: 17721096
Drug: Interleukin-2 therapy
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2 therapy (subcutaneous IL-2, median of ten 5-day cycles)
Study: 7648827
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin (1.8U over 15 min)
Study: 8006126
Drug: Progesterone supplementation
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone supplementation (i.m. progesterone at a daily dose of 25‐50 mg for 14 days)
Study: 15380907
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement
Study: 26543357
Drug: Linseed oil
Normalized name: linseed oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linseed oil supplementation (3 g/day)
Study: 24927607
Drug: Filibuvir 300
Normalized name: Filibuvir
DrugBank: Filibuvir (DB11878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filibuvir 300 mg BID plus pegIFN/ribavirin
Study: 1293261
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg preservative-free morphine
Study: 22912450
Drug: YDC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: YDC treatment
Study: 10450540
Drug: Mud packs
Normalized name: aminophylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Tablet [Mudrane GG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud packs combined with antidepressant treatment (trazodone)
Study: 10338176
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tramadol
Study: 8389738
Drug: Captopril (C)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (C) 25, 50, or 100 mg b.i.d.
Study: 19064627
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine
Study: 8330828
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of butylscopolamine bromide i.v. (BSB)
Study: 31623758
Drug: 12-month DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month DAPT followed by 12-month aspirin monotherapy
Study: 31290965
Drug: Esketamine 84
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 84 mg plus oral antidepressant
Study: 16971315
Drug: Tetracycline 1
Normalized name: tetracycline 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 1 g daily for 1 month, then 500 mg daily for 2 months